Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer

Nivolumab, a human monoclonal antibody against programmed death‐1, is approved for the treatment of non–small cell lung cancer (NSCLC). Although nivolumab is generally well tolerated, it can cause interstitial lung disease (ILD), a rare but potentially fatal immune‐related adverse event. Currently,...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Sci
Prif Awduron: Sata, Masafumi, Sasaki, Shinichi, Oikado, Katsunori, Saito, Yoshinobu, Tominaga, Junya, Sakai, Fumikazu, Kato, Terufumi, Iwasawa, Tae, Kenmotsu, Hirotsugu, Kusumoto, Masahiko, Baba, Tomohisa, Endo, Masahiro, Fujiwara, Yutaka, Sugiura, Hiroaki, Yanagawa, Noriyo, Ito, Yoshihiko, Sakamoto, Takahiko, Ohe, Yuichiro, Kuwano, Kazuyoshi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2021
Pynciau:
ORIGINAL ARTICLES
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8019226/
https://ncbi.nlm.nih.gov/pubmed/33125784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14715
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg